Market Trends of Global Sepsis Diagnostics Industry
The Molecular Diagnostics Segment Has a Significant Share in the Market
Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis detection.
Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform. This is one of the first rapid, fully integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.
Furthermore, researchers are attempting to develop molecular diagnostics that can detect COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis, in part funded by Sanmina Corporation, developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of the sepsis diagnostics market segment.
North America is Expected to Hold a Large Share of the Market
North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus boosting the market.
Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 million contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus driving the North America sepsis diagnostic market outlook.
Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in the United States.